ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "corticosteroids"

  • Abstract Number: L19 • ACR Convergence 2023

    A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks

    George Spencer-Green1, David Hunter2, Thomas Schnitzer3, Sheue-Fang Shih4, Tien-Tzu Tai4, Cathy Kao4 and Siao-Ning Huang4, 1Taiwan Liposome Company, Cambridge, MA, 2Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Taiwan Liposome Company, Taipei, Taiwan (Republic of China)

    Background/Purpose: In osteoarthritis (OA) of the knee, intraarticular injections of corticosteroids can relieve pain, reduce inflammation, and improve mobility, but the effect is not predictable,…
  • Abstract Number: 1133 • ACR Convergence 2023

    Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center

    William Rigby1, Todd Mackenzie2, Emily Campbell1, Joshua Skydel3, Bryan Savage1, Monica Dimambro2 and Vivekanand Tiwari1, 1Dartmouth Hitchcock Medical Center, Lebanon, NH, 2Dartmouth College, Hanover, NH, 3Dartmouth-Hitchcock Medical Center, Lebanon, NH

    Background/Purpose: Polymyalgia rheumatica (PMR) treatment is primarily based on long-term corticosteroids, which results in significant toxicities. Studies1,2 have shown that patients with PMR are exposed…
  • Abstract Number: 1327 • ACR Convergence 2023

    Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials

    Andriko Palmowski1, Sabrina Mai Nielsen2, Zhivana Boyadzhieva3, Linda Hartman4, Judith Oldenkott5, Björn Svensson6, Ingiäld Hafström7, Siegfried Wassenberg8, Ernest Choy9, John Kirwan10, Robin Christensen11, Maarten Boers12 and Frank Buttgereit13, 1Charité - Universitätsmedizin Berlin, Berlin, Germany, 2The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, 3Charité Universitatsmedizine - Berlin, Berlin, Germany, 4Amsterdam University Medical Centers, Amsterdam, Netherlands, 5Charite - University Medicine Berlin, Berlin, Germany, 6Lund University, Lund, Sweden, 7Karolinska Institutet, Stockholm, Sweden, 8Rheumazentrum Ratingen, Ratingen, Germany, 9Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, 10University of Bristol, Bristol, United Kingdom, 11Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 12Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, 13Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany

    Background/Purpose: High-dose glucocorticoids (GCs) can cause weight gain and hypertension. It is unclear whether GCs at ≤7.5mg/day prednisone equivalent ("low dose"), administered for rheumatoid arthritis…
  • Abstract Number: 1446 • ACR Convergence 2023

    Glucocorticoids Use Is a Major Driver of Self-perceived Depression in Systemic Lupus Erythematosus: Insights from a Large, Prospective and Multicenter Study Using RELESSERPROS Register’s Database

    Iñigo Rúa-Figueroa1, JULIA MARTINEZ BARRIO2, Norman Jiménez3, Maria Galindo-Izquierdo4, Esther Uriarte Isacelaya5, Antonio Fernandez-Nebro6, Jaime Calvo- Alén7, SARA MANRIQUE8, Jose Rosas9, Rocío Caño-Alameda10, Javier Narvaez11, Inmaculada Ros12, Elena Aurrecoechea Aguinaga13, Vicente Torrente-Segarra14, Clara Sanguesa Gomez15, Mercedes Freire González16, Eva Tomero Muriel17, Loreto Horcada18, Clara Moriano Morales19, Mireia Moreno20, Carlota Iñíguez21, Ricardo Blanco22, Ana Pérez Gómez23, Jose Luis Andreu-Sánchez24, Sandra Garrote Corral25, Santiago Muñoz26, Gema Bonilla27, Nuria Lozano Rivas28, Carlos Montilla-Morales29, Oihane Ibarguengoitia-Barrena30, Lorena Expósito31, Elia Valls-Pascual32, Angela Pecondon-Español33, Sergio Machin34, Eva Salgado-Pérez35, Celia Erausquin36, TAREK CARLOS SALMAN MONTE37, Raúl Menor-Almagro38, Alejandro Muñoz39, Irene Altabas Gonzalez40, Jorge Juan Fragio41 and Jose-Maria Pego-Reigosa42, 1Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 2Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, 3IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, 4Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, 5Rheumatology, University Hospital of Donosti, San Sebastián, Spain, 6Hospital Regional Universitario de Málaga, Malaga, Spain, 7Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, 8Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, 9Hospital Marina Baixa, Alicante, Spain, 10Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, 11Hospital Universitario de Bellvitge, Barcelona, Spain, 12Rheumatology Department HUSLL, Palma de Mallorca, Spain, 13Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, 14Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, 15Severo Ochoa Hospital, Madrid, Spain, 16Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 17Rheumatology, Hospital La Princesa, Madrid, Spain, 18Hospital de Navarra, Pamplona, Spain, 19Rheumatology, Hospital Universitario de León, León, Spain, 20Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, 21Hospital Lucus Augusti, Lugo, Spain, 22Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 23Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, 24Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, 25Hospital Ramón y Cajal, Madrid, Spain, 26Hospital Infanta Sofia, Madrid, Spain, 27Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, 28Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 29Rheumatology, University Hospital of Salamanca, Salamanca, Spain, 30Galdakao-Usansolo University Hospital, Bilbao, Spain, 31Rheumatology Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, 32Hospital Universitario Doctor Peset. Alicante, Spain., Valencia, Spain, 33Hospital Miguel Servet, Zaragoza, Spain, 34CHUIMI, Las Palmas de Gran Canaria, Spain, 35Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, 36Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, 37Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, 38Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, 39Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, 40Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, 41Hospital General Universitario Valencia, Valencia, Spain, 42Rheumatology, Hospital do Meixoeiro, Vigo, Spain

    Background/Purpose: The prevalence of depression and associated factors in systemic lupus erythematosus (SLE) are not well known and there are no longitudinal studies addressing this…
  • Abstract Number: 1523 • ACR Convergence 2023

    The Risk of Scleroderma Renal Crisis from Intraarticular Corticosteroid Injection in Systemic Sclerosis

    Muruganandam Maheswari, Eyerusalem Akpan, Matthew Mcelwee, Meredith Keller, Angie Ariza - Hutchinson, Rosemina Patel, Wilmer Sibbitt, Frank O'Sullivan, Sharon nunez, N. Suzanne Emil and Roderick Fields, University of New Mexico, Albuquerque, NM

    Background/Purpose: Scleroderma renal crisis (SRC) is a rare but a life-threatening complication of systemic sclerosis (SSc), affecting 2-15% of patients with SSc. SRC has been…
  • Abstract Number: 1840 • ACR Convergence 2023

    Value of Various Intra-Articular Injections for Knee Osteoarthritis Management

    Hanna Mass1, Jamie Collins1, david Hunter2, Catherine Yang1, Morgan Jones1, Stephen Messier3, Tuhina Neogi4, A. David Paltiel5, Jeffrey Katz1 and Elena Losina6, 1Brigham and Women's Hospital, Boston, MA, 2Sydney Musculoskeletal Health, University of Sydney, St. Leonards, Australia, 3Wake Forest University, Winston-Salem, NC, 4Boston University School of Medicine, Boston, MA, 5Yale School of Public health, New Haven, CT, 6Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Intra-articular injections (IAI) are commonly used to relieve pain and delay total knee replacement (TKR) in persons with knee OA. Despite higher costs and…
  • Abstract Number: 1988 • ACR Convergence 2023

    Extended-Release versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis of the Knee with Comorbid Diabetes Type 2 Diabetes Mellitus: A Post Hoc Analysis

    Andrew Spitzer1, Helena Rodbard2, Sheikh Usman Iqbal3, Masato Nakazawa3, Mary DiGiorgi3 and Roy Winston3, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2Endocrine and Metabolic Consultants, Rockville, MD, 3Pacira BioSciences, Inc., Tampa, FL

    Background/Purpose: Intraarticular (IA) corticosteroids are generally considered safe and effective to treat osteoarthritis of the knee (OAK) but may cause hyperglycemia that may last for…
  • Abstract Number: 2307 • ACR Convergence 2023

    Comparing Social Vulnerability Index to Area Deprivation Index to Patient Outcomes in SLE and Glucocorticoid Utilization

    Avira Som1, Lily McMorrow1, Ling Chen1, Deepali Sen2, Elizabeth Baker3 and Alfred Kim4, 1Washington University School of Medicine in St. Louis, St. Louis, MO, 2Washington University in St. Louis, St. Louis, MO, 3Saint Louis University, St. Louis, MO, 4Washington University School of Medicine, St. Louis, MO

    Background/Purpose: As shown in previous studies, outcomes in SLE are affected by social determinants of health which influence health care disparities. Evaluating health disparities through…
  • Abstract Number: 2498 • ACR Convergence 2023

    Does Physical Activity Modify the Relationship Between Pain and Corticosteroid Injection Utilization in Adults with or at High Risk for Knee Osteoarthritis?

    Sydney Liles1, Daniel White2, Thomas Bye2 and Jason Jakiela2, 1University of Delaware, Elkton, MD, 2University of Delaware, Newark, DE

    Background/Purpose: Knee osteoarthritis (OA) is a leading global cause of pain and disability, with no current cure. Knee pain is the most common symptom and…
  • Abstract Number: 0208 • ACR Convergence 2023

    Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System

    Angela Bobak1, Emely Pimentel1, Jordan Jackson2, Celia Gray3, Hema Srinivasan3, Andrea Berger3 and David Bulbin3, 1Geisinger Medical Center Internal Medicine Residency, Danville, PA, 2Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, 3Geisinger Health System, Danville, PA

    Background/Purpose: PJP is an opportunistic fungus causing significant morbidity and mortality in immunocompromised patients.  Guidelines describe PJP PPX indications among non-HIV infected individuals with cancer…
  • Abstract Number: 0587 • ACR Convergence 2023

    Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data

    Daniel Moldaver1, Seth Anderson2, Marguerite Bracher3, Roger A. Levy4, Holly A. Quasny5, Robert Wood6, Rosie Wild6, Alexandra Cusmano6 and Elke Rottier6, 1GlaxoSmithKline, Value Evidence and Outcomes, Ontario, Canada, 2GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA, 3GlaxoSmithKline, Value Evidence and Outcomes, Stevenage, United Kingdom, 4GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 5GlaxoSmithKline, Research & Development, Durham, NC, 6Adelphi Real World, Real-World Evidence, Cheshire, United Kingdom

    Background/Purpose: The clinical effectiveness of 6-month IV BEL use in SLE has previously been described in a post hoc pooled analysis from six OBSErve cohort…
  • Abstract Number: 0678 • ACR Convergence 2023

    Benralizumab in Eosinophilic Granulomatosis with Polyangiitis

    Adrien Cottu1, Matthieu Groh2, Charlène Desaintjean3, Sylvain Marchand-Adam4, Loic Guillevin5, Xavier Puéchal6, Estibaliz Lazaro7, Maxime Samson8, Camille Taillé9, Cécile-Audrey Durel10, Elisabeth Diot11, Sarah Nicolas11, Laurent Guilleminault12, Mikael Ebbo13, Pascal Cathébras14, Clairelyne Dupin9, Halil Yildiz15, Nabil Belfeki16, Gregory Pugnet17, Pierre Chauvin18, Stephane Jouneau19, François Lifermann20, Jean-Philippe Martellosio21, Vincent Cottin22 and Benjamin Terrier23, 1Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 2National Referral Center for Hypereosinophilic Syndrome (CEREO), Hôpital Foch, Suresnes, France, 3Department of Respiratory Diseases, Hôpital Louis Pradel, Lyon, France, 4CHRU Tours, service de pneumologie et d'explorations fonctionnelles respiratoires, Tours, France, 5University Paris Descartes, Paris, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 7Bordeaux Hospital University, Pessac, France, 8Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 9AP-HP, Bichat Hospital, Reference Center for Rare Pulmonary Diseases and University of Paris Cité, Inserm 1152, Paris, France, 10CHU Lyon, Lyon, France, 11Service de médecine interne et immunologie clinique, CHU Tours, Tours, France, 12Department of respiratory and allergic diseases, Toulouse University Hospital Center, Toulouse, France, 13Aix Marseille Univ, APHM, hôpital de la Timone, Internal Medicine Department, Marseille, France, 14Department of Internal medicine, Hôpital Nord, CHU St Etienne, Saint-Etienne, France, 15Saint Luc Hospital, Bruxelles, Belgium, 16Service de Médecine Interne et Immunologie Clinique. Groupe Hospitalier Sud Île de France, Melun, France, 17CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, 18Department of Respiratory Diseases, Rennes University Hospital, Rennes, France, 19Amicus, Boca Raton, FL, 20Department of Internal Medicine, Centre Hospitalier de Dax, Dax, France, 21Service de médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France, 22Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, 23Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Gucocorticoid (GC)-dependant asthma and ENT exacerbations may persist in more than 80% of eosinophilic granulomatosis with polyangiitis (EGPA). The MIRRA trial demonstrated the efficacy…
  • Abstract Number: 0725 • ACR Convergence 2023

    Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis

    Sophie Nagle1, Yann Nguyen2, Xavier Puéchal3, Dimitri Titeca-Beauport4, Thomas Crépin5, Rafik Mesbah6, Idris Boudhabhay7, Gregory Pugnet8, Juliette Woessner9, Roderau Outh10, Céline Lebas11, Antoine Néel12, alexandre Karras13, Eric Hachulla11, Benjamin Subran14, Philippe Kerschen15, Mathieu Gerfaud-Valentin16, Stéphane Vinzio17, Tiphaine Goulenok18, Raphael Borie19, Sébastien Humbert20, Yurdagul Uzunhan21, Sarah Melboucy-Belkhir22, Jean-Baptiste Gouin23, Mary-Jane Guerry24 and Benjamin Terrier25, 1AP-HP Cochin Hospital, Paris, France, 2Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 4CHU Amiens, Amiens, France, 5Amiens University Hospital, Amiens, France, 6Boulogne Hospital (CH), Boulogne, France, 7Necker University Hospital, Paris, France, 8CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, 9Avignon Hospital (CH), Avignon, France, 10Perpignan Hospital (CH), Perpignan, France, 11Lille University Hospital, Lille, France, 12CHU Nantes, Nantes, France, 13HEGP - APHP, Paris, France, 14Croix Saint Simon Hospital, Paris, France, 15Department of Neurology, Luxembourg Hospital Center, Luxembourg City, Luxembourg, 16Lyon University Hospital, Lyon, France, 17Grenoble Hospital (CH), Grenoble, France, 18Assistance Publique Hopitaux de Paris, Paris, France, 19Bichat-Claude Bernard, Universite de Paris, Paris, France, 20Besançon University Hospital, Besançon, France, 21AP-HP, Bobigny, France, 22Saint Quentin Hospital, Saint-Quentin, France, 23Vannes Hospital (CH Bretagne Atlantique), Vannes, France, 24Valenciennes Hospital (CH), Valenciennes, France, 25Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with severe granulomatosis with polyangiitis (GPA) and microscopic…
  • Abstract Number: 0990 • ACR Convergence 2023

    Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry

    Kelly Gavigan1, Esteban Rivera2, Odette Kolenky3, Cassie Clinton4, Emily Holladay4, David Curtis5, Laura Stradford6, Jeffrey Curtis4, W. Benjamin Nowell6, Christian Curtis7 and Michael George8, 1Global Healthy Living Foundation, Upper Nyack, NY, 2Global Healthy Living Foundation, Long Island City, NY, 3Hospital of the University of Pennsylvania, Philadelphia, PA, 4University of Alabama at Birmingham, Birmingham, AL, 5Global Healthy Living Foundation, San Francisco, CA, 6Global Healthy Living Foundation, Nyack, NY, 7Illumination Health, Birmingham, AL, 8University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Infections are a major contributor to morbidity and mortality in patients (pts) with rheumatoid arthritis (RA). Little is known about the risk of non-serious…
  • Abstract Number: 024 • 2023 Pediatric Rheumatology Symposium

    Effects of Corticosteroids on Central Nervous System Microvascular Properties Assessed by Neuroimaging

    Mark DiFrancesco, Ekemini Ogbu, Catherine Robben, Jennifer Huggins and Hermine Brunner, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Prior research suggests that microvascular (MV) changes might be a biomarker for central nervous system (CNS) involvement of patients with systemic lupus erythematosus (SLE).…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology